Synergistic Blend of Standardized herbal extracts for Eye Health
MacOlene
Macolene - Eye health formula
MacOlene is a Patented, natural, synergistic herbal composition developed for Eye health
​
Study involving ARPE and HUVEC cell line models in a single study, proves its benefits in AMD and diabetic retinopathy. It was found to downregulate VEGF secretion in ARPE (Retinal pigment epithelial cells) cells and also inhibits neovascularization in HUVEC cells
AMD is the main cause for heavy Vision in old age in the western Industrial countries.(1)
AMD concerns every fourth European over 60 years.(2)
AGE-RELATED MACULAR DEGENERATION DIASEAE PROGRESSION
Age-related macular degeneration (AMD) is an eye disease affecting the macula of the retina causing blurred vision or loss of central vision. AMD is one of the leading cause of vision loss in people over 50 years of age. It occurs in two forms, “Dry” form which is most common and “wet” form which is less common but more severe than the dry form and characterised by formation of neovascularization. VEGF (Vascular Endothelial Growth Factor) & PDGF (Platelet Derived Growth Factor) are major potent stimulators of wet AMD. While there is no specific treatment for AMD as such, vitamin combinations with lutein and zeaxanthin are found to be beneficial in the case of dry form and anti-VEGF intro-ocular injections are shown to be helpful in people with wet-AMD.
MECHANISM OF MACOLENE
MacOlene has the following machanism of action:
-
VEGF down-regulating activity
-
VEGF binding activity
-
PDGF inhibitory activity
-
Anti-neovascular
VEGF - Vascular Endothelial Growth Factor
PDGF - Platelet Derived Growth Factor
EFFICACY STUDIES
-
VEGF down-regulating activity in ARPE (Human Retinal Pigment Epithelial Cell lines)
-
VEGF binding activity in induced ARPE cell supernatant
-
Inhibition of formatio of new blood vessels in HUVEC
(Human umbilical vein endothelial cells)
Efficacy of the MacOlene was proven through a cell line study using ARPE cells and HUVEC cells in the single study to mimic the in vivo pathophysiological conditions, where the ARPE cells are stimulated to produce VEGF, which is further used for stimulating HUVEC cells to form neovascularisation. MacOlene was show to have:
VEGF DOWN - REGULATING ACTIVITY OF MACOLENE
VEGF binding activity of MacOlene was evaluated in induced
ARPE cell supernatant containing VEGF.
-
VEGF downregulating activity of MacOlene was evaluated in ARPE cells
-
MacOlene was tested in two different dosage forms: Oral and Ophthalmic
-
There was a 58.49% and 59.38% downregulation of VEGF for oral and opthalmic formulation
VEGF BINDING ACTIVITY OF MACOLENE
VEGF binding activity of MacOlene was evaluated in induced ARPE cell supernatant containing VEGF.
-
MacOlene was tested in two different dosage forms: Oral and Opthalmic
-
It achieved massive 83.98% and 70.58% binding of VEGF for oral and ophalmic formulation respectively
INHIBITION NEOVASCULARIZATION BY MACOLENE
Inhibition neovascularization by MacOlene was tested by inducing neovascularization in HUVEC cells using VEGF released from ARPE cells. MacOlene showed significant inhibition of tube formation observed in HUVEC cells
MACOLENE PRODUCTS
MACOLENE (Formula BASE)
MACOLENE PLUS - (Formula + Lutein + Zeaxanthin)
MACOLENE BERRY- (Forumla + Bilberry) - soon
MacOlene is a trademark of Olene Life Sciences Pvt.Ltd., India
Registration of TMEU is pending
​
-
(1) WHO - Blindness and vision impairment (https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment)
-
(2) Universättsklinikum Boon - Retinal Diseases in Europe Prevalence, incidence and healthcare needs (https://miloftalmica.it/wp-content/uploads/2021/07/Euretina-Retinal-Diseases.pdf)
